Trial Watch: Monoclonal antibodies in cancer therapy

• Published in: Oncoimmunology Vol. 1; no. 1; pp. 28 - 37
• Main Authors: Galluzzi, Lorenzo, Vacchelli, Erika, Fridman, Wolf Hervé, Galon, Jerome, Sautès-Fridman, Catherine, Tartour, Eric, Zucman-Rossi, Jessica, Zitvogel, Laurence, Kroemer, Guido
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 01.01.2012; Landes Bioscience
• Subjects: bevacizumab; Binding; Biology; Bioscience; Calcium; Cancer; Cell; Cycle; dalotuzumab; ipilimumab; Landes; nimotuzumab; Organogenesis; Proteins; ramucirumab; Review; trastuzumab

Since the advent of hybridoma technology, dating back to 1975, monoclonal antibodies have become an irreplaceable diagnostic and therapeutic tool for a wide array of human diseases. During the last 15 years, several monoclonal antibodies (mAbs) have been approved by FDA for cancer therapy. These mAb...